# 119-s-1041: Affordable Prescriptions for Patients Act

119-s-1041, Affordable Prescriptions for Patients Act, is a 119th Congress bill sponsored by Sen. Cornyn, John [R-TX] (R-TX); status passed_senate; PRIA reads it as touching household money (as of 2026-08-11).

- Canonical: https://policyrisk.com/legislation/119-s-1041
- As of: 2026-08-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-s-1041
- Congress: 119
- Title: Affordable Prescriptions for Patients Act
- Status: passed_senate
- Introduced: 2025-03-13
- Sponsor: Sen. Cornyn, John [R-TX] (R-TX)
- Cosponsors: 3
- Policy area: Commerce
- Touches household money: yes
- Last recorded action: 2026-08-11

## Summary

**Limits how many patents a biologic drug maker can assert against a biosimilar applicant.** The bill would cap certain patent assertions in biosimilar litigation while also expanding the kinds of patents that can be claimed to include manufacturing-method and manufacturing-product patents. - If a biosimilar applicant completes the information-sharing steps under the FDA biosimilar pathway, the reference product sponsor may assert up to 20 patents in an infringement suit and no more than 10 of those may have issued after a specified date. - Only patents that are listed and that either were filed more than four years after the reference product’s approval or claim a manufacturing-process method not used by the reference sponsor count toward the cap, narrowing some late-filed patent claims. - Courts can increase the cap for the interest of justice or for good cause and may consider whether the reference sponsor gave a reasonable description of extra information needed to support additional infringement claims.

## Cosponsors (3)

- Sen. Blumenthal, Richard [D-CT] (D-CT), 2025-03-13T00:00:00.000Z
- Sen. Grassley, Chuck [R-IA] (R-IA), 2025-03-13T00:00:00.000Z
- Sen. Durbin, Richard J. [D-IL] (D-IL), 2025-03-13T00:00:00.000Z

## Provisions PRIA read

- Limits and new rules for biosimilar patents: mixed, medium. If enacted, this would set a 20-patent cap for lawsuits tied to an FDA biosimilar application filed after enactment. No more than 10 of those could be later-issued patents listed after the post-approval listing date in the biologics law. The cap would not cover patents on methods of using the drug…

## Related bills

- 119-s-1071: National Defense Authorization Act for Fiscal Year 2026
- 119-s-1748: Kids Online Safety Act
- 119-s-539: PROTECT Our Children Reauthorization Act of 2025
- 119-s-5025: Lindsey O. Graham Sanctioning Russia Act of 2026
- 119-s-1241: Sanctioning Russia Act of 2025
- 119-s-545: Combating Illicit Xylazine Act

## Sources
- [119-s-1041 on Congress.gov](https://www.congress.gov/bill/119th-congress/senate-bill/1041)

## Related
- [119-s-1071: National Defense Authorization Act for Fiscal Year 2026](https://policyrisk.com/legislation/119-s-1071)
- [119-s-1748: Kids Online Safety Act](https://policyrisk.com/legislation/119-s-1748)
- [119-s-539: PROTECT Our Children Reauthorization Act of 2025](https://policyrisk.com/legislation/119-s-539)
- [119-s-5025: Lindsey O. Graham Sanctioning Russia Act of 2026](https://policyrisk.com/legislation/119-s-5025)
- [119-s-1241: Sanctioning Russia Act of 2025](https://policyrisk.com/legislation/119-s-1241)
- [119-s-545: Combating Illicit Xylazine Act](https://policyrisk.com/legislation/119-s-545)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-s-1041 (as of 2026-08-11).